| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CIL56 | CTRPv2 | pan-cancer | AAC | -0.0069 | 0.9 |
| mRNA | CGP-60474 | GDSC1000 | pan-cancer | AAC | -0.0077 | 0.9 |
| mRNA | BRD-A71883111 | CTRPv2 | pan-cancer | AAC | -0.0052 | 0.9 |
| mRNA | BRD-K70511574 | CTRPv2 | pan-cancer | AAC | -0.0044 | 0.9 |
| mRNA | masitinib | CTRPv2 | pan-cancer | AAC | 0.005 | 0.9 |
| mRNA | PD-0332991 | FIMM | pan-cancer | AAC | 0.022 | 0.9 |
| mRNA | compound 1B | CTRPv2 | pan-cancer | AAC | 0.0052 | 0.9 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | tamatinib | CTRPv2 | pan-cancer | AAC | -0.0049 | 0.9 |
| mRNA | Curcumin | CTRPv2 | pan-cancer | AAC | -0.0045 | 0.9 |